Sanofi, GSK say Covid booster shot works better against Omicron variant

The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations.

Coronavirus vaccines, booster shot
Photo: Bloomberg
Deirdre Hipwell | Bloomberg
2 min read Last Updated : Jun 13 2022 | 7:30 PM IST
Sanofi and GSK Plc, the pharma giants that fell behind in the race to develop a Covid-19 shot, said their experimental booster vaccine delivers a more powerful immune response against coronavirus variants than their competitors’. 
 
The shot raised antibody levels in adults already inoculated with messenger RNA vaccines more than the additional doses from Pfizer Inc. and BioNTech SE, and demonstrated potential to protect against variants including omicron, GSK and Sanofi said in a statement Monday, citing data from two trials. 

Shares in Sanofi and GSK were little changed in early trading. 

The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations. The “next-generation” vaccine includes GSK’s pandemic adjuvant -- a substance that enhances the immune response to vaccines -- and is modeled on the beta variant.

In one late-stage trial, the Sanofi-GSK booster induced a significant increase in antibodies against multiple variants compared to the original parent virus booster. In particular, it generated double the number of neutralizing antibodies against omicron BA.1 and BA.2. 

A second independent study of 247 people, conducted by the Assistance Publique - Hopitaux de Paris, showed that the shot induced a higher immune response than both Pfizer-BioNTech’s booster and Sanofi-GSK’s first-generation booster, both of which target the original parent strain of the virus. 

All the data from the two trials will be submitted to regulatory authorities in the coming weeks with the aim of making the shot available later this year. 

Sanofi and Glaxo, two of the vaccine industry’s biggest players, have been trying to show they still have a role to play in the fight against Covid after a dosing error early in the pandemic forced them to restart a clinical trial.

The Sanofi-Glaxo inoculation has some potential advantages over most of the existing Covid shots. It can be kept at refrigerator temperatures, making it easier to transport and store than the mRNA shots. But the companies face new rivals and a market with rising supplies and declining demand. 

Sanofi-GSK Covid-Vaccine Booster May Not Have Any Utility: React

The two companies have developed their booster in parallel to ongoing regulatory reviews of their first-generation vaccine shot. Earlier this year they found their vaccine protects against severe disease and hospitalization.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :OmicronSanofi GSKCoronavirus VaccinePfizer

Next Story